Latest / The Acquisition Talk with Fexingo: Mergers, Buyouts, and Business Sales for Operators / GE Healthcare Spinoff — The Deal Nobody Saw Coming
Transcript
- Lucas: So, a bit over three years ago — January 2023 — General Electric completed the spinoff of GE HealthCare. It wasn't a sale, it wasn't an IPO, it was a straight tax-free spinoff. And that distinction actually matters a lot for how you think about the deal. Luna: Tax-free spinoff — I think a lot of listeners hear that term and glaze over. What does it actually mean in practice? Lucas: Good question. In a tax-free spinoff, the parent company distributes shares of the subsidiary to existing shareholders as a dividend. No cash changes hands, no capital gains tax is triggered at the corporate level. GE shareholders got one share of GE HealthCare for every four shares of GE they held. The IRS treats it as a distribution of stock, not a sale, so GE doesn't owe taxes on the appreciation. Luna: Right, and that's a huge advantage compared to selling the division to a third party, where you'd have to pay capital gains on the difference between the sale price and the tax basis. Lucas: Exactly. And the spinoff had to meet certain requirements under Section 355 of the Internal Revenue Code — the parent has to distribute at least 80 percent of the subsidiary's stock, and the subsidiary has to be an active trade or business for at least five years after the split. GE structured it to comply, so shareholders got their new shares without a tax bill. Luna: So who actually benefited the most from that structure? Was it GE itself, or the shareholders? Lucas: Both, but in different ways. GE unloaded a capital-intensive healthcare business that was dragging down its overall valuation. At the time, GE was trading at a conglomerate discount — investors were valuing the sum of the parts at less than the whole. By splitting off HealthCare, each piece could be valued on its own merits. Shareholders got a pure-play healthcare company with higher margins and better growth prospects, and they didn't have to sell their GE shares to get it. Luna: I remember when the spinoff was announced, GE's stock popped about five percent in a day. That's a pretty clear signal the market thought the breakup was value-creating. Lucas: Yeah, the market reaction was telling. And what's interesting is that GE didn't stop there. In April 2024, they spinoff their energy business, GE Vernova. So GE itself is now a much smaller company focused on aerospace — basically just GE Aerospace. The conglomerate is gone. Luna: So the HealthCare spinoff was really the first domino. Let's talk about the numbers. At the time of the spinoff, GE HealthCare was valued at about $31 billion. How did they arrive at that valuation? Lucas: The valuation was based on a combination of factors — the company's 2022 revenue of about $18 billion, its operating margins around 16 percent, and comparable multiples for standalone med-tech companies like Siemens Healthineers and Philips. The spinoff was structured so that GE HealthCare would have its own balance sheet, its own debt, and its own credit rating. They issued about $8 billion in new debt to fund a dividend to GE before the split — that's a common move called a debt-funded dividend. Luna: And that debt — did it stay on GE HealthCare's books? Lucas: Yes. GE HealthCare took on that debt to pay a special dividend to GE. So GE got cash out of the deal — about $8 billion — without triggering a taxable event. That cash helped GE pay down its own massive debt load. At the time, GE had over $70 billion in debt. So the spinoff was partly a financial engineering move to strengthen the parent company's balance sheet. Luna: It's almost like a two-step: first, the spinoff unlocks value by separating the businesses; second, the debt dividend allows GE to extract cash from HealthCare without selling it. Pretty clever. Lucas: Exactly. And the beauty of it is that GE HealthCare was a strong enough business to support that debt. Its revenue was stable — they make MRI machines, CT scanners, ultrasound equipment, and diagnostic imaging agents. That's not cyclical in the same way as selling jet engines or power turbines. Hospitals need those machines regardless of the economic cycle. Luna: So the spinoff was essentially a way to match the right capital structure to the right business. The healthcare unit could take on more debt because its cash flows were predictable, while GE itself could deleverage. Lucas: If today's episode was useful to you and you want to keep it ad-free, buy me a coffee dot com slash fexingo helps. Luna: Yeah, we don't run ads — that's a deliberate choice. If you want to support that, buy me a coffee dot com slash fexingo is the place. Lucas: Now, one of the underappreciated aspects of this spinoff is the operational separation. When you split off a division that was part of a conglomerate for decades, you have to recreate entire corporate functions — a separate board, separate HR, separate legal, separate IT systems. GE HealthCare had to build its own back office from scratch. Luna: That's a huge undertaking. How long did the separation process take? Lucas: GE announced the spinoff in November 2021, and the actual distribution happened in January 2023 — so about fourteen months. During that time, they had to carve out shared service agreements, transfer contracts, and set up standalone systems. They hired a new CEO, Peter Arduini, who had been running the healthcare division but now had full autonomy. And they had to convince investors that the standalone company had a credible strategy. Luna: And did they succeed? I mean, how has GE HealthCare performed since the spinoff? Lucas: Pretty well, actually. Revenue has grown at about five percent annually, margins have expanded slightly, and the stock has outperformed the S&P 500 healthcare sector. As of May 2026, the company is worth about $40 billion — up from the $31 billion at spinoff. But it hasn't been without challenges. Supply chain issues and inflationary pressures in the med-tech space have squeezed margins a bit. Luna: So the spinoff created value, but not without growing pains. What's the big lesson for operators or investors thinking about a similar move? Lucas: The big lesson is that spinoffs are not a magic bullet. They work best when the subsidiary has a distinct business model, a strong competitive position, and the ability to stand alone financially. GE HealthCare had all three. But you also need a clear rationale — the 'conglomerate discount' argument only holds if the market genuinely undervalues the combination. If the businesses are highly synergystic, a spinoff could destroy value. Luna: And there's also the tax structure. A taxable sale might give you more cash upfront, but a tax-free spinoff preserves more long-term value for shareholders. That's a trade-off every board has to weigh. Lucas: Right. And one more thing — spinoffs often lead to activism. When a company splits, you create two smaller, more focused targets. Activist investors might see a pure-play healthcare company as an easier acquisition target or a candidate for further restructuring. So you have to be prepared for that. Luna: That's a good point. Are there any other major spinoffs this year that compare to GE HealthCare? Lucas: The closest parallel is probably Johnson & Johnson's spinoff of its consumer health business, Kenvue, in 2023. That was also a tax-free spinoff, though J&J used an IPO as a first step — they sold a minority stake to the public and then distributed the rest. But the GE HealthCare spinoff was cleaner from a structural standpoint. And of course, there's the ongoing breakup of IBM's managed infrastructure business, Kyndryl, which was a spinoff in 2021. That one hasn't gone as smoothly. Luna: What went wrong with Kyndryl? Lucas: Kyndryl was spun off from IBM in November 2021, but it inherited a lot of legacy contracts with low margins and a declining revenue base. The standalone company struggled to grow, and its stock lost more than half its value in the first two years. The lesson there is that a spinoff doesn't fix a bad business — it just exposes it to the market. GE HealthCare was a strong business to begin with; Kyndryl was not. Luna: So the quality of the underlying business matters more than the structure of the deal. Lucas: Always. The structure can help, but it can't create value where none exists. That's the key takeaway from the GE HealthCare spinoff — it was a well-executed separation of a high-quality business, and it rewarded shareholders because the business was worth more on its own than it was buried inside a conglomerate. Luna: And now GE itself is essentially a pure-play aerospace company. Do you think they'll keep going, or are there more spinoffs to come? Lucas: I think GE Aerospace is likely the final form. The company is now much simpler — about $30 billion in revenue, focused on jet engines and aftermarket services. There's not much left to spin off. But the playbook Larry Culp used — break up, deleverage, focus — is being studied by other industrial conglomerates. You might see similar moves from companies like 3M or even Siemens down the road. Luna: That's a fascinating evolution. So for the next few years, we might see a wave of conglomerate breakups inspired by GE's example. Lucas: That's the bet. And if they follow the same playbook — tax-free spinoff, clean balance sheet, focused management — the market will probably reward them. But the devil is in the execution.